A study on expression of androgen receptor in triple negative breast cancer

Background: Triple-Negative Breast Cancer (Tnbc) Represents A Biologically Aggressive Subtype Lacking Oestrogen Receptor (Er), Progesterone Receptor (Pr), And Her2 Expression, Leaving Limited Targeted Therapeutic Options. The Androgen Receptor (Ar) Has Emerged As A Potential Biomarker And Therapeutic Target In Tnbc. Objectives: This Study Aims To Assess Ar Expression In Tnbc And Correlate It With Various Clinico Pathological Parameters. Methods: A Prospective Observational Study Was Conducted On 56 Histologically Confirmed Tnbc Cases At Sree Balaji Medical College And Hospital From August 2023 To March 2025. Immuno Histochemistry Was Performed Using A Rabbit Monoclonal Anti-Ar Antibody (Clone Ep120). Ar Expression Was Scored Based On Both Intensity And Proportion. Associations With Clinico Pathological Features Were Analyzed Using Fisher's Exact Test And T-Tests. A P-Value < 0.05 Was Considered Statistically Significant. Results: Ar Positivity Was Observed In 17 Of 56 Tnbc Cases (30%). Significant Associations Were Found Between Ar Expression And Tumor Grade (P = 0.015) And Ki-67 Proliferation Index (P = 0.003). No Statistically Significant Associations Were Observed Between Ar Status And Age, Tumor Size, Nodal Status, Laterality, Histological Subtype, Lympho Vascular Invasion, Or Tnm Stage. Conclusion:Ar Expression In Tnbc Is Significantly Associated With Higher Tumour Grade And Increased Proliferative Activity. While Ar Was Not Correlated With Other Clinico Pathological Parameters, Its Expression May Hold Prognostic And Therapeutic Significance. Larger Studies With Standardized Criteria Are Required To Clarify Its Role In Tnbc Management.